-
Je něco špatně v tomto záznamu ?
Follistatin-like 1 and its paralogs in heart development and cardiovascular disease
M. Horak, D. Fairweather, P. Kokkonen, D. Bednar, J. Bienertova-Vasku
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, přehledy, Research Support, N.I.H., Extramural, práce podpořená grantem
Grantová podpora
R21 AI145356
NIAID NIH HHS - United States
R21 AI152318
NIAID NIH HHS - United States
R21 AI154927
NIAID NIH HHS - United States
NLK
ProQuest Central
od 1999-01-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2005-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1999-01-01 do Před 1 rokem
- MeSH
- biologické markery MeSH
- fibróza MeSH
- folistatin MeSH
- kardiovaskulární nemoci * MeSH
- lidé MeSH
- proteiny související s folistatinem * genetika metabolismus MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
- Research Support, N.I.H., Extramural MeSH
Cardiovascular diseases (CVDs) are a group of disorders affecting the heart and blood vessels and a leading cause of death worldwide. Thus, there is a need to identify new cardiokines that may protect the heart from damage as reported in GBD 2017 Causes of Death Collaborators (2018) (The Lancet 392:1736-1788). Follistatin-like 1 (FSTL1) is a cardiokine that is highly expressed in the heart and released to the serum after cardiac injury where it is associated with CVD and predicts poor outcome. The action of FSTL1 likely depends not only on the tissue source but also post-translation modifications that are target tissue- and cell-specific. Animal studies examining the effect of FSTL1 in various models of heart disease have exploded over the past 15 years and primarily report a protective effect spanning from inhibiting inflammation via transforming growth factor, preventing remodeling and fibrosis to promoting angiogenesis and hypertrophy. A better understanding of FSTL1 and its homologs is needed to determine whether this protein could be a useful novel biomarker to predict poor outcome and death and whether it has therapeutic potential. The aim of this review is to provide a comprehensive description of the literature for this family of proteins in order to better understand their role in normal physiology and CVD.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22032908
- 003
- CZ-PrNML
- 005
- 20230131151313.0
- 007
- ta
- 008
- 230120s2022 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s10741-022-10262-6 $2 doi
- 035 __
- $a (PubMed)35867287
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Horak, Martin $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, Brno, 625 00, Czech Republic $u Research Centre for Toxic Compounds in the Environment, Faculty of Science, Masaryk University, Kamenice 5, Brno, 625 00, Czech Republic
- 245 10
- $a Follistatin-like 1 and its paralogs in heart development and cardiovascular disease / $c M. Horak, D. Fairweather, P. Kokkonen, D. Bednar, J. Bienertova-Vasku
- 520 9_
- $a Cardiovascular diseases (CVDs) are a group of disorders affecting the heart and blood vessels and a leading cause of death worldwide. Thus, there is a need to identify new cardiokines that may protect the heart from damage as reported in GBD 2017 Causes of Death Collaborators (2018) (The Lancet 392:1736-1788). Follistatin-like 1 (FSTL1) is a cardiokine that is highly expressed in the heart and released to the serum after cardiac injury where it is associated with CVD and predicts poor outcome. The action of FSTL1 likely depends not only on the tissue source but also post-translation modifications that are target tissue- and cell-specific. Animal studies examining the effect of FSTL1 in various models of heart disease have exploded over the past 15 years and primarily report a protective effect spanning from inhibiting inflammation via transforming growth factor, preventing remodeling and fibrosis to promoting angiogenesis and hypertrophy. A better understanding of FSTL1 and its homologs is needed to determine whether this protein could be a useful novel biomarker to predict poor outcome and death and whether it has therapeutic potential. The aim of this review is to provide a comprehensive description of the literature for this family of proteins in order to better understand their role in normal physiology and CVD.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a biologické markery $7 D015415
- 650 12
- $a kardiovaskulární nemoci $7 D002318
- 650 _2
- $a fibróza $7 D005355
- 650 _2
- $a folistatin $7 D038681
- 650 12
- $a proteiny související s folistatinem $x genetika $x metabolismus $7 D038702
- 650 _2
- $a lidé $7 D006801
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 655 _2
- $a Research Support, N.I.H., Extramural $7 D052061
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Fairweather, DeLisa $u Department of Cardiovascular Medicine, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA
- 700 1_
- $a Kokkonen, Piia $u Research Centre for Toxic Compounds in the Environment, Faculty of Science, Masaryk University, Kamenice 5, Brno, 625 00, Czech Republic
- 700 1_
- $a Bednar, David $u Research Centre for Toxic Compounds in the Environment, Faculty of Science, Masaryk University, Kamenice 5, Brno, 625 00, Czech Republic
- 700 1_
- $a Bienertova-Vasku, Julie $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, Brno, 625 00, Czech Republic. Julie.dobrovolna@med.muni.cz $u Research Centre for Toxic Compounds in the Environment, Faculty of Science, Masaryk University, Kamenice 5, Brno, 625 00, Czech Republic. Julie.dobrovolna@med.muni.cz $1 https://orcid.org/000000015327808X
- 773 0_
- $w MED00007617 $t Heart failure reviews $x 1573-7322 $g Roč. 27, č. 6 (2022), s. 2251-2265
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35867287 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230120 $b ABA008
- 991 __
- $a 20230131151309 $b ABA008
- 999 __
- $a ok $b bmc $g 1891579 $s 1184243
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2022 $b 27 $c 6 $d 2251-2265 $e 20220722 $i 1573-7322 $m Heart failure reviews $n Heart Fail Rev $x MED00007617
- GRA __
- $a R21 AI145356 $p NIAID NIH HHS $2 United States
- GRA __
- $a R21 AI152318 $p NIAID NIH HHS $2 United States
- GRA __
- $a R21 AI154927 $p NIAID NIH HHS $2 United States
- LZP __
- $a Pubmed-20230120
